Evevogs-GM 2 Tablet SR is a combination oral antidiabetic medication containing Glimepiride (2mg), Metformin (500mg), and Voglibose (0.2mg), designed to effectively manage type 2 diabetes mellitus. Glimepiride, a sulfonylurea, stimulates pancreatic beta cells to increase insulin secretion, thereby lowering blood glucose levels. Metformin, a biguanide, primarily reduces hepatic glucose production and improves insulin sensitivity, enhancing peripheral glucose uptake. Voglibose, an alpha-glucosidase inhibitor, delays carbohydrate absorption in the intestines, preventing postprandial blood sugar spikes. The sustained-release formulation ensures a gradual release of active ingredients, promoting better glycemic control with reduced dosing frequency and minimizing gastrointestinal side effects commonly associated with immediate-release forms. Evevogs-GM 2 Tablet SR is indicated for patients inadequately controlled on diet and exercise alone or those requiring combination therapy to achieve target blood glucose levels. It should be used under medical supervision, with regular monitoring of blood glucose and renal function. Common side effects may include mild gastrointestinal discomfort, hypoglycemia, or allergic reactions. Patients are advised to adhere to prescribed doses and lifestyle modifications to maximize therapeutic benefits and reduce the risk of complications associated with diabetes.